This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (415)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Endocrine Diseases  • Diabetes Mellitus  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

The STOP-NIDDM Trial

Jean-Louis Chiasson, MD; Robert G. Josse, MBBS; Ramon Gomis, MD; Markolf Hanefeld, DSC; Avraham Karasik, MD; Markku Laakso, MD; for The STOP-NIDDM Trial Research Group

JAMA. 2003;290:486-494.

Context  The worldwide explosive increase in type 2 diabetes mellitus and its cardiovascular morbidity are becoming major health concerns.

Objective  To evaluate the effect of decreasing postprandial hyperglycemia with acarbose, an -glucosidase inhibitor, on the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance (IGT).

Design, Setting, and Participants  International, multicenter double-blind, placebo-controlled, randomized trial, undertaken in hospitals in Canada, Germany, Austria, Norway, Denmark, Sweden, Finland, Israel, and Spain from July 1998 through August 2001. A total of 1429 patients with IGT were randomized with 61 patients (4%) excluded because they did not have IGT or had no postrandomization data, leaving 1368 patients for a modified intent-to-treat analysis. Both men (49%) and women (51%) participated with a mean (SD) age of 54.5 (7.9) years and body mass index of 30.9 (4.2). These patients were followed up for a mean (SD) of 3.3 (1.2) years.

Intervention  Patients with IGT were randomized to receive either placebo (n = 715) or 100 mg of acarbose 3 times a day (n = 714).

Main Outcome Measures  The development of major cardiovascular events (coronary heart disease, cardiovascular death, congestive heart failure, cerebrovascular event, and peripheral vascular disease) and hypertension (140/90 mm Hg).

Results  Three hundred forty-one patients (24%) discontinued their participation prematurely, 211 in the acarbose-treated group and 130 in the placebo group; these patients were also followed up for outcome parameters. Decreasing postprandial hyperglycemia with acarbose was associated with a 49% relative risk reduction in the development of cardiovascular events (hazard ratio [HR], 0.51; 95% confidence interval [CI]; 0.28-0.95; P = .03) and a 2.5% absolute risk reduction. Among cardiovascular events, the major reduction was in the risk of myocardial infarction (HR, 0.09; 95% CI, 0.01-0.72; P = .02). Acarbose was also associated with a 34% relative risk reduction in the incidence of new cases of hypertension (HR, 0.66; 95% CI, 0.49-0.89; P = .006) and a 5.3% absolute risk reduction. Even after adjusting for major risk factors, the reduction in the risk of cardiovascular events (HR, 0.47; 95% CI, 0.24-0.90; P = .02) and hypertension (HR, 0.62; 95% CI, 0.45-0.86; P = .004) associated with acarbose treatment was still statistically significant.

Conclusion  This study suggests that treating IGT patients with acarbose is associated with a significant reduction in the risk of cardiovascular disease and hypertension.

Author Affiliations: Research Centre, Centre Hospitalier de l'Université de Montréal–Hôtel-Dieu and Department of Medicine, Université de Montréal, Montreal, Quebec (Dr Chiasson); Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario (Dr Josse); Diabetes Unit, Hospital Clinic, Universitari de Barcelona, Barcelona, Spain (Dr Gomis); Centre for Clinical Studies GWT, Dresden Technical University, Dresden, Germany (Handefeld); Institute of Endocrinology, Chaim Sheba Medical Centre, Tel Hashomer, Israel (Dr Karasik); and Department of Medicine, University of Kuopio, Kuopio, Finland (Dr Laakso).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Julian H. Rosenthal
JAMA. 2003;290(23):3066.
EXTRACT | FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Thomas Kaiser and Peter T. Sawicki
JAMA. 2003;290(23):3066.
EXTRACT | FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
Claude M. Bridges
JAMA. 2003;290(23):3066-3067.
EXTRACT | FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance
José-Miguel González-Clemente, Emilio Ortega-Martínez de Victoria, Olga Giménez-Palop, and Dídac Mauricio
JAMA. 2003;290(23):3067.
EXTRACT | FULL TEXT  

Acarbose for Patients With Hypertension and Impaired Glucose Tolerance—Reply
Jean-Louis Chiasson, Robert G. Josse, Ramon Gomis, Markolf Hanefeld, Avraham Karasik, and Markku Laakso
JAMA. 2003;290(23):3067-3069.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
Gallwitz
Diabetes Care 2009;32:S322-S325.
FULL TEXT  

Is Hyperglycemia a Causal Factor in Cardiovascular Disease?: Does proving this relationship really matter? Yes
Davidson and Parkin
Diabetes Care 2009;32:S331-S333.
FULL TEXT  

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
Bianchi et al.
Diabetes Care 2009;32:S342-S348.
FULL TEXT  

Shifting the Disease Management Paradigm From Glucose: What are the cons?
Hanefeld et al.
Diabetes Care 2009;32:S353-S356.
FULL TEXT  

Prehypertension is associated with insulin resistance
Hwu et al.
QJM 2009;102:705-711.
ABSTRACT | FULL TEXT  

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
Riddle et al.
Diabetes Care 2009;32:1577-1582.
ABSTRACT | FULL TEXT  

Dietary Carbohydrates and Cardiovascular Disease Risk Factors in the Framingham Offspring Cohort
McKeown et al.
J. Am. Coll. Nutr. 2009;28:150-158.
ABSTRACT | FULL TEXT  

The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease
Cheng et al.
Journal of Pharmacy Practice 2009;22:179-193.
ABSTRACT  

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
Raz et al.
Diabetes Care 2009;32:381-386.
ABSTRACT | FULL TEXT  

Postprandial Hyperglycemia and Cardiovascular Disease: Is the HEART2D study the answer?
Ceriello
Diabetes Care 2009;32:521-522.
FULL TEXT  

Topics in Type 2 Diabetes and Insulin Resistance
Bloomgarden
Diabetes Care 2009;32:e13-e19.
FULL TEXT  

Baseline ICAM-1 and VCAM-1 Are Increased in Initially Healthy Middle-Aged Men Who Develop Cardiovascular Disease During 6.6 Years of Follow-Up
Schmidt et al.
ANGIOLOGY 2009;60:108-114.
ABSTRACT  

Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications
Lindsey et al.
Diabetes and Vascular Disease Research 2009;6:7-14.
ABSTRACT  

Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial
Hanefeld et al.
Diabetes and Vascular Disease Research 2009;6:32-37.
ABSTRACT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Clin. Diabetes 2009;27:4-16.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Spectr. 2009;22:6-17.
FULL TEXT  

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Care 2009;32:193-203.
ABSTRACT | FULL TEXT  

CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome
Cosentino et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT | FULL TEXT  

Effect of a Low-Glycemic Index or a High-Cereal Fiber Diet on Type 2 Diabetes: A Randomized Trial
Jenkins et al.
JAMA 2008;300:2742-2753.
ABSTRACT | FULL TEXT  

Lifestyle interventions reduced the long-term risk of diabetes in adults with impaired glucose tolerance
Raina Elley and Kenealy
Evid. Based Med. 2008;13:173-173.
FULL TEXT  

The Metabolic Syndrome
Cornier et al.
Endocr. Rev. 2008;29:777-822.
ABSTRACT | FULL TEXT  

Cardiovascular effects of acute hyperglycaemia: pathophysiological underpinnings
Ceriello
Diabetes and Vascular Disease Research 2008;5:260-268.
ABSTRACT  

Implications of abnormal glucose metabolism in patients with coronary artery disease
Anselmino et al.
Diabetes and Vascular Disease Research 2008;5:285-290.
ABSTRACT  

American College of Endocrinology Pre-Diabetes Consensus Conference: Part Two
Bloomgarden
Diabetes Care 2008;31:2222-2229.
FULL TEXT  

Glycemic Management of Type 2 Diabetes: How Tight Is Right and How to Get There
Nathan
Arch Intern Med 2008;168:2064-2066.
FULL TEXT  

Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus
de Boer et al.
Arch Intern Med 2008;168:1867-1873.
ABSTRACT | FULL TEXT  

Approach to the Patient with Prediabetes
Aroda and Ratner
J. Clin. Endocrinol. Metab. 2008;93:3259-3265.
ABSTRACT | FULL TEXT  

Approaches to Treatment of Pre-Diabetes and Obesity and Promising New Approaches to Type 2 Diabetes
Bloomgarden
Diabetes Care 2008;31:1461-1466.
FULL TEXT  

Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force
Norris et al.
ANN INTERN MED 2008;148:855-868.
ABSTRACT | FULL TEXT  

The importance of treating cardiometabolic risk factors in patients with type 2 diabetes
Barnett
Diabetes and Vascular Disease Research 2008;5:9-14.
ABSTRACT  

Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme
Snehalatha et al.
Diabetes and Vascular Disease Research 2008;5:25-29.
ABSTRACT  

Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus
McGuire et al.
Diabetes and Vascular Disease Research 2008;5:59-66.
ABSTRACT  

Effect of cereal test breakfasts differing in glycemic index and content of indigestible carbohydrates on daylong glucose tolerance in healthy subjects
Nilsson et al.
Am. J. Clin. Nutr. 2008;87:645-654.
ABSTRACT | FULL TEXT  

Hydroxypropylmethylcellulose and Methylcellulose Consumption Reduce Postprandial Insulinemia in Overweight and Obese Men and Women
Maki et al.
J. Nutr. 2008;138:292-296.
ABSTRACT | FULL TEXT  

Natural History of Cardiovascular Disease in Patients With Diabetes: Role of hyperglycemia
Milicevic et al.
Diabetes Care 2008;31:S155-S160.
ABSTRACT | FULL TEXT  

New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Inzucchi and McGuire
Circulation 2008;117:574-584.
ABSTRACT | FULL TEXT  

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart
Anselmino et al.
Eur Heart J 2008;29:177-184.
ABSTRACT | FULL TEXT  

Review: Postprandial glycaemia and cardiovascular risk
Peter and Rees
British Journal of Diabetes & Vascular Disease 2008;8:8-14.
ABSTRACT  

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes
Lund et al.
Eur J Endocrinol 2008;158:35-46.
ABSTRACT | FULL TEXT  

Glucose metabolism and hyperglycemia
Giugliano et al.
Am. J. Clin. Nutr. 2008;87:217S-222S.
ABSTRACT | FULL TEXT  

Lessons From the Avandia Controversy: A new paradigm for the development of drugs to treat type 2 diabetes
Misbin
Diabetes Care 2007;30:3141-3144.
FULL TEXT  

Type 1 Diabetes and Glucose Monitoring
Bloomgarden
Diabetes Care 2007;30:2965-2971.
FULL TEXT  

Diabetes Treatment, Part 2: Oral Agents for Glycemic Management
Fowler
Clin. Diabetes 2007;25:131-134.
FULL TEXT  

Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPAR{alpha}/{gamma} agonist, tesaglitazar
Fagerberg et al.
Diabetes and Vascular Disease Research 2007;4:174-180.
ABSTRACT  

Extract of Salacia oblonga lowers acute glycemia in patients with type 2 diabetes
Williams et al.
Am. J. Clin. Nutr. 2007;86:124-130.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT  

Review: Pre-diabetes: clinical relevance and therapeutic approach
Pratley and Matfin
British Journal of Diabetes & Vascular Disease 2007;7:120-129.
ABSTRACT  

High-Viscosity Hydroxypropylmethylcellulose Blunts Postprandial Glucose and Insulin Responses
Maki et al.
Diabetes Care 2007;30:1039-1043.
ABSTRACT | FULL TEXT  

Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician
Kikano and Brown
Mayo Clin Proc. 2007;82:583-593.
ABSTRACT | FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al.
Jellinger et al.
Diabetes Care 2007;30:e16-e17.
FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Jellinger, Lebovitz, and Davidson
Davidson
Diabetes Care 2007;30:e18-e20.
FULL TEXT  

Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care
Nathan et al.
Diabetes Care 2007;30:753-759.
FULL TEXT  

Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
Wilcox et al.
Stroke 2007;38:865-873.
ABSTRACT | FULL TEXT  

Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach
Gerstein
Diabetes Care 2007;30:432-434.
FULL TEXT  

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al.
Parkin and Davidson
Diabetes Care 2007;30:192-193.
FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Cryer, Porta and Trento, and Parkin and Davidson
Nathan and On Behalf of the ADA/DASD Consensus Group
Diabetes Care 2007;30:194-196.
FULL TEXT  

Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart
Bartnik et al.
Heart 2007;93:72-77.
ABSTRACT | FULL TEXT  

Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents
Ajjan and Grant
Diabetes and Vascular Disease Research 2006;3:147-158.
ABSTRACT  

Prediction of Postprandial Glycemic Exposure: Utility of fasting and 2-h glucose measurements alone and in combination with assessment of body composition, fitness, and strength
Cohen et al.
Diabetes Care 2006;29:2708-2713.
ABSTRACT | FULL TEXT  

Almonds Decrease Postprandial Glycemia, Insulinemia, and Oxidative Damage in Healthy Individuals
Jenkins et al.
J. Nutr. 2006;136:2987-2992.
ABSTRACT | FULL TEXT  

Glycemic treatment in type 1 and type 2 diabetes.
Bloomgarden
Diabetes Care 2006;29:2549-2555.
FULL TEXT  

Postprandial hyperglycaemia and vascular damage - the benefits of acarbose
Bavenholm and Efendic
Diabetes and Vascular Disease Research 2006;3:72-79.
ABSTRACT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Care 2006;29:1963-1972.
FULL TEXT  

Lowering dietary glycemic load for weight control and cardiovascular health: a matter of quality.
Liu
Arch Intern Med 2006;166:1438-1439.
FULL TEXT  

Clinicians can help their patients control postprandial hyperglycemia as a means of reducing cardiovascular risk.
Gerich
The Diabetes Educator 2006;32:513-522.
ABSTRACT | FULL TEXT  

Combined Treatment With Exercise Training and Acarbose Improves Metabolic Control and Cardiovascular Risk Factor Profile in Subjects With Mild Type 2 Diabetes
Wagner et al.
Diabetes Care 2006;29:1471-1477.
ABSTRACT | FULL TEXT  

Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis: A 7-year observational study
Oomichi et al.
Diabetes Care 2006;29:1496-1500.
ABSTRACT | FULL TEXT  

All Pre-Diabetes Is Not the Same: Metabolic and Vascular Risks of Impaired Fasting Glucose at 100 Versus 110 mg/dl: The Screening for Impaired Glucose Tolerance Study 1 (SIGT 1).
Phillips et al.
Diabetes Care 2006;29:1405-1407.
FULL TEXT  

Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes
Haffner
Eur Heart J Suppl 2006;8:B20-B25.
ABSTRACT | FULL TEXT  

Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes
Monnier et al.
JAMA 2006;295:1681-1687.
ABSTRACT | FULL TEXT  

Influence of Metabolic Syndrome and General Obesity on the Risk of Ischemic Stroke
Chen et al.
Stroke 2006;37:1060-1064.
ABSTRACT | FULL TEXT  

Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice
Liao et al.
Cardiovasc Res 2006;70:107-116.
ABSTRACT | FULL TEXT  

Postprandial Blood Glucose Is a Stronger Predictor of Cardiovascular Events Than Fasting Blood Glucose in Type 2 Diabetes Mellitus, Particularly in Women: Lessons from the San Luigi Gonzaga Diabetes Study
Cavalot et al.
J. Clin. Endocrinol. Metab. 2006;91:813-819.
ABSTRACT | FULL TEXT  

Effects of a Single Administration of Acarbose on Postprandial Glucose Excursion and Endothelial Dysfunction in Type 2 Diabetic Patients: A Randomized Crossover Study
Shimabukuro et al.
J. Clin. Endocrinol. Metab. 2006;91:837-842.
ABSTRACT | FULL TEXT  

Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes
Woerle et al.
Am. J. Physiol. Endocrinol. Metab. 2006;290:E67-E77.
ABSTRACT | FULL TEXT  

Review: {alpha} glucosidase inhibitors improve glycaemic control but have uncertain effects on patient-important outcomes in type 2 diabetes
Isley
Evid. Based Med. 2005;10:174-174.
FULL TEXT  

Laparoscopic Gastric Banding Prevents Type 2 Diabetes and Arterial Hypertension and Induces Their Remission in Morbid Obesity: A 4-year case-controlled study
Pontiroli et al.
Diabetes Care 2005;28:2703-2709.
ABSTRACT | FULL TEXT  

Postprandial Hyperglycemia Is a Better Predictor of the Progression of Diabetic Retinopathy Than HbA1c in Japanese Type 2 Diabetic Patients
Shiraiwa et al.
Diabetes Care 2005;28:2806-2807.
FULL TEXT  

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy et al.
Circulation 2005;112:2735-2752.
FULL TEXT  

Differences in Cardiovascular Risk Factors, Insulin Resistance, and Insulin Secretion in Individuals With Normal Glucose Tolerance and in Subjects With Impaired Glucose Regulation: The Telde Study
Novoa et al.
Diabetes Care 2005;28:2388-2393.
ABSTRACT | FULL TEXT  

Glycated and Oxidized Protein Degradation Products Are Indicators of Fasting and Postprandial Hyperglycemia in Diabetes
Ahmed et al.
Diabetes Care 2005;28:2465-2471.
ABSTRACT | FULL TEXT  

Enteral Nutritional Support and Use of Diabetes-Specific Formulas for Patients With Diabetes: A systematic review and meta-analysis
Elia et al.
Diabetes Care 2005;28:2267-2279.
ABSTRACT | FULL TEXT  

Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects
Chaikomin et al.
Am. J. Physiol. Endocrinol. Metab. 2005;289:E504-E507.
ABSTRACT | FULL TEXT  

Metformin's contraindications should be contraindicated
McCormack et al.
CMAJ 2005;173:502-504.
FULL TEXT  

Changing the Definition of Impaired Fasting Glucose: Impact on the classification of individuals and risk definition
Vaccaro and Riccardi
Diabetes Care 2005;28:1786-1788.
ABSTRACT | FULL TEXT  

{alpha}-Glucosidase Inhibitors for Patients With Type 2 Diabetes: Response to van de Laar et al.
Hanefeld et al.
Diabetes Care 2005;28:1840-1840.
FULL TEXT  

Oral Agents for Type 2 Diabetes: An Update
Kimmel and Inzucchi
Clin. Diabetes 2005;23:64-76.
ABSTRACT | FULL TEXT  

Primary Prevention of Cardiovascular Disease in Pre-Diabetes: The glass is half full and half empty
Dagogo-Jack
Diabetes Care 2005;28:971-972.
FULL TEXT  

Effects of Pramlintide on Postprandial Glucose Excursions and Measures of Oxidative Stress in Patients With Type 1 Diabetes
Ceriello et al.
Diabetes Care 2005;28:632-637.
ABSTRACT | FULL TEXT  

A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes
Padwal et al.
Diabetes Care 2005;28:736-744.
ABSTRACT | FULL TEXT  

Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes
Ceriello et al.
Diabetes Care 2005;28:266-272.
ABSTRACT | FULL TEXT  

Prevalence of Abnormal Glucose Tolerance Following a Transient Ischemic Attack or Ischemic Stroke
Kernan et al.
Arch Intern Med 2005;165:227-233.
ABSTRACT | FULL TEXT  

Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care
Feig et al.
CMAJ 2005;172:177-180.
FULL TEXT